Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International Open-Label Extension of Phase 3 Study CL-503012 with Kiacta in AA Amyloidosis
2013-004150-16Phase 3Terminated
- Sponsor
- A.T. Development
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eprodisate in AA amyloidosis, sponsored by A.T. Development. Primary endpoint: Primary safety and effectiveness collection. Started Apr 2014; status: terminated.
02
Drugs
eprodisate
03
Conditions
AA amyloidosis
Beyond the preview
Go deeper on 2013-004150-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004150-16.